OKYO Pharma Ltd ADR
$ 1.99
-1.97%
26 Dec - close price
- Market Cap 89,890,000 USD
- Current Price $ 1.99
- High / Low $ 2.13 / 1.97
- Stock P/E N/A
- Book Value -0.15
- EPS -0.12
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.70 %
- ROE -29.69 %
- 52 Week High 3.35
- 52 Week Low 0.90
About
OKYO Pharma Ltd ADR is a London-based preclinical biopharmaceutical company dedicated to pioneering innovative therapies targeting inflammatory eye diseases and ocular pain. With a focus on addressing significant unmet medical needs in the ophthalmology field, the company is advancing a strategically prioritized pipeline that aims to revolutionize ocular therapeutics. OKYO Pharma's commitment to scientific excellence and rigorous research positions it well for future growth and the potential to enhance the quality of life for patients suffering from challenging eye conditions. As it progresses through the complexities of drug development, OKYO Pharma is positioned to make a meaningful impact within the specialized market of ocular health.
Analyst Target Price
$10.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-22 | 2025-08-05 | 2025-03-31 | 2025-01-29 | 2024-09-30 | 2024-07-30 | 2024-03-31 | 2024-01-09 | 2023-12-28 | 2023-08-15 |
| Reported EPS | None | -0.06 | None | -0.08 | None | -0.09 | None | -0.1 | -0.11 | -0.34 |
| Estimated EPS | -0.04 | -0.05 | -0.05 | -0.09 | -0.09 | -0.09 | -0.09 | -0.1 | -0.11 | -0.11 |
| Surprise | 0 | -0.01 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | -0.23 |
| Surprise Percentage | None% | -20% | None% | 11.1111% | None% | 0% | None% | 0% | 0% | -209.0909% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.04 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OKYO
2025-12-20 12:08:59
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its Executive Chairman and Founder, Gabriele Cerrone, along with the management team, will ring the Opening Bell at the Nasdaq MarketSite in Times Square on Friday, December 19, 2025. This event recognizes the company's work in developing new treatments, specifically its lead candidate urcosimod for neuropathic corneal pain. The announcement was made via a Form 6-K filing with the SEC.
2025-12-20 12:08:59
OKYO Pharma Ltd, an ophthalmology-focused biopharmaceutical company developing urcosimod for neuropathic corneal pain, visited the Nasdaq MarketSite. Gabriele Cerrone, Executive Chairman and Founder, rang the Opening Bell to mark the occasion. The event took place in Times Square, New York, on December 19, 2025.
2025-12-20 12:08:48
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its Executive Chairman and Founder, Gabriele Cerrone, along with the management team, will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York, on Friday, from 9:15 AM to 9:30 AM Eastern Time. This event recognizes the company's work in developing new treatments, specifically its lead candidate, urcosimod, for neuropathic corneal pain. The company is headquartered in London and listed on Nasdaq.
2025-12-19 15:30:04
This "Small cap wrap" article highlights several companies' recent developments. Happy Creek Minerals announced drill results from its Fox tungsten project, Abacus Global Management revealed plans to transfer its stock listing to the NYSE, and OKYO Pharma is scheduled to ring the Nasdaq Opening Bell. Additionally, Gunnison Copper is partnering with Lunasonde for advanced sensing technology, Caledonia Mining saw its shares rise due to amended Zimbabwean royalty laws, and Mirriad Advertising anticipates lower full-year revenue.
2025-12-19 14:09:04
OKYO Pharma Ltd. (NASDAQ:OKYO), a clinical-stage biopharmaceutical company, announced that its management team will ring the Nasdaq Opening Bell, marking the company's progress in developing treatments for neuropathic corneal pain (NCP). The event highlights their ongoing efforts, including positive Phase 2 clinical trial results for their lead drug candidate, urcosimod, which showed favorable outcomes for corneal nerve measures and pain reduction in NCP patients.
2025-12-19 13:46:00
OKYO Pharma announced that executive chairman and founder Gabriele Cerrone, along with members of the company’s management team, will ring the Nasdaq Opening Bell. This event celebrates the company's progress in developing treatments for neuropathic corneal pain (NCP), an ocular condition with no FDA-approved therapies. The company highlighted positive Phase 2 clinical trial results for its lead drug candidate, urcosimod, showing favorable outcomes in corneal nerve measures and pain reduction.
